Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17274929 | 0.82 | ACHE (0.46) | KDM4EHSD17B10TSHRPOLBALDH1A1 | |
| SCHEMBL28629227 | 0.82 | KDM4E (0.64) | KDM4EHSD17B10CYP1A2CYP3A4TSHR | |
| SCHEMBL18631590 | 0.80 | KDM4E (0.62) | KDM4EHSD17B10CYP1A2CYP3A4TSHR | |
| SCHEMBL16740709 | 0.72 | NPC1 (0.68) | KDM4EHSD17B10CYP1A2CYP3A4TSHR | |
| SCHEMBL17275513 | 0.70 | NPC1 (0.56) | KDM4EHSD17B10CYP1A2CYP3A4TSHR | |
| SCHEMBL29946446 | 0.69 | CDK4 (0.55) | KDM4ECYP3A4TSHRALDH1A1LMNA | |
| SCHEMBL542799 | 0.69 | CDK4 (0.55) | KDM4ECYP3A4TSHRALDH1A1LMNA | |
| Quinoline SCHEMBL27857139 | 0.69 | AHR (0.62) | KDM4EHSD17B10CYP1A2CYP3A4TSHR | |
| SCHEMBL27354475 | 0.69 | NPC1 (0.68) | KDM4EHSD17B10CYP1A2CYP3A4TSHR | |
| SCHEMBL28772072 | 0.69 | ADORA3 (0.55) | KDM4ECYP1A2LMNACYP2C19GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| WO-2015179218-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | AZI2, DNMT1, TET3 | KDM4E 232/4885HSD17B10 1179/4885CYP1A2 31/4885 |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | AZI2, DNMT1, TET3 | KDM4E 232/4885HSD17B10 1179/4885CYP1A2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.